Supplement Table S1. Demographic and disease-related characteristics adjusted with Propensity Weighting.

Characteristic	Crude		p-Value	Weighted		p-Value
	No Statin	Statin		No Statin	Statin	
Age (yrs; mean, SD)	85 (8)	82 (7)	<0.001	84 (8)	84 (7)	0.521
Sex (Female; *n*, %)	551 (71%)	257 (66%)	0.061	528 (70%)	232 (67%)	0.352
Type (*n*, %)						
Atorvastatin		184 (74%)			143 (43%)	
Simvastatin		91 (23%)			101 (30%)	
Rosuvastatin		87 (22%)			68 (20%)	
Pravastatin		27 (6.9%)			22 (6.6%)	
Surgery Performed (yes; *n*, %)	758 (98%)	382 (98%)	0.906	753 (99%)	382 (98%)	0.457
CCI (mean, SD)	6 (2)	7 (2)	0.357	7 (3)	7 (2)	0.210
ASA grade (mean, SD)			0.169			0.362
1	7 (0.9%)	0 (0%)		6 (0.7%)	0 (0%)	
2	110 (14%)	64 (17%)		102 (14%)	43 (12%)	
3	439 (58%)	229 (60%)		436 (58%)	198 (57%)	
4	203 (27%)	88 (27%)		212 (28%)	103 (30%)	
5	2 (0.3%)	2 (0.5%)		2 (0.2%)	2 (0.7%)	
RCRI (median, range)			<0.001			0.016
0	438 (57%)	132 (34%)		364 (48%)	140 (40%)	
1	216 (28%)	144 (37%)		228 (30%)	128 (37%)	
2	93 (12%)	70 (18%)		101 (13%)	53 (15%)	
3	21 (2.7%)	36 (9.2%)		37 (4.8%)	23 (6.5%)	
4	6 (0.8%)	8 (2.0%)		28 (3.7%)	4 (1.1%)	
5	1 (0.1%)	1 (0.3%)		1 (0.1%)	1 (0.1%)	
Cardiac-related Comorbidity						
Ischaemic Heart Disease	160 (21%)	157 (40%)	<0.001	217 (29%)	117 (34%)	0.077
Congestive Cardiac Failure	115 (15%)	59 (15%)	0.910	142 (19%)	54 (16%)	0.194
Cerebrovascular Disease	216 (28%)	155 (40%)	<0.001	243 (32%)	113 (33%)	0.857
Hypertension	451 (58%)	280 (72%)	<0.001	472 (62%)	230 (66%)	0.204
Peripheral Vascular Disease	45 (5.8%)	35 (9.0%)	0.045	43 (5.6%)	25 (7.3%)	0.302
Previous Acute Pulmonary Oedema	37 (4.8%)	41 (10%)	<0.001	51 (6.7%)	25 (7.3%)	0.730
Existing Atrial Fibrillation	215 (19%)	5 (16%)	0.503	156 (21%)	63 (18%)	0.329
Valvular heart disease	25 (3.2%)	14 (3.6%)	0.750	25 (3.3%)	10 (3.0%)	0.772
Prosthetic valve	6 (0.8%)	7 (1.8%)	0.119	5 (0.7%)	5 (1.4%)	0.284
Aortic aneurysm	18 (2.3%)	19 (4.9%)	0.020	21 (2.7%)	12 (3.4%)	0.571
Pacemaker	23 (3.0%)	15 (3.8%)	0.430	21 (2.7%)	17 (5.0%)	0.056
Non-cardiac Comorbidity						
Chronic Renal Failure	81 (10%)	69 (18%)	<0.001	114 (15%)	50 (14%)	0.752
Diabetes Mellitus	104 (13%)	116 (30%)	<0.001	158 (21%)	74 (21%)	0.839

Gastro-oesophageal Reflux Disease	215 (28%)	134 (34%)	0.022	214 (28%)	109 (32%)	0.253
Chronic Obstructive Pulmonary Disease	117 (15%)	62 (16%)	0.734	111 (15%)	53 (15%)	0.761
Malignancy	153 (19%)	71 (18%)	0.517	137 (18%)	77 (22%)	0.109
Dementia	235 (30%)	82 (21%)	<0.001	225 (30%)	105 (30%)	0.854
Hypercholesterolaemia	67 (8.6%)	210 (54%)	<0.001	182 (24%)	92 (27%)	0.368
Medications						
Antitplatelets	235 (30%)	223 (57%)	<0.001	303 (40%)	158 (45%)	0.090
Beta blocker	188 (24%)	169 (43%)	<0.001	230 (30%)	123 (35%)	0.097
Calcium channel blocker	100 (13%)	86 (22%)	<0.001	104 (14%)	75 (22%)	<0.001
Angiotensin converting enzyme inhibitor	91 (12%)	122 (31%)	<0.001	170 (22%)	108 (31%)	<0.001
Angiotensin Receptor Blocker	91 (12%)	79 (20%)	<0.001	102 (13%)	56 (16%)	0.240
Frusemide	195 (25%)	111 (28%)	0.237	220 (29%)	111 (28%)	0.237
Spironolactone	50 (6.5%)	39 (10%)	0.032	65 (8.6%)	23 (6.6%)	0.255
Ezetimibe	7 (0.9%)	6 (1.5%)	0.332	14 (1.9%)	3 (0.9%)	0.195
Nitroavasodilators	124 (16%)	73 (19%)	0.251	117 (15%)	80 (23%)	<0.001
NSAID	23 (3.0%)	9 (2.3%)	0.511	26 (3.5%)	14 (3.9%)	0.722
Corticosteroids	59 (7.6%)	18 (4.6%)	0.051	61 (8.0%)	10 (3.0%)	<0.001

ASA- American Society of Anesthesiologists, CCI- Charlson Comorbidity Index, NSAID- non-steroidal anti-inflammatory drug, RCRI- Revised Cardiac Risk Index.